The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) phase.
Go to Source
https://medicalxpress.com/rss-feed/
Go to Source
https://medicalxpress.com/rss-feed/